TY - JOUR
T1 - Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy
T2 - Secondary Analysis of the WAVE Randomized Trial
AU - Ou, William C
AU - Lampen, Shaun I R
AU - Wykoff, Charles C
N1 - Funding Information:
Originally submitted June 3, 2017. Revision received October 23, 2017. Accepted for publication December 4, 2017. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting, 2017. The study was supported by a research grant from Genentech, South San Francisco, CA. The funding organization had no role in the design or conduct of this research. Dr. Wykoff reports grants from Genentech during the conduct of the study, as well as grants and personal fees from Alcon Laboratories, Allergan, Clearside Biomedical, Genentech, Iconic Therapeutics, and Regeneron; personal fees from Alimera Sciences, Alnylam Pharmaceuticals, D.O.R.C., ONL Therapeutics, Thrombogenics, and Valeant; and grants from Allegro, Aura, Bayer, NEI, NIH, Novartis, OHR Pharmaceuticals, Ophthotech, pSivida, Roche, Santen, SciFluor Life Sciences, and Tyrogenex outside the submitted work. Address correspondence to Charles C. Wykoff, MD, PhD, 6560 Fannin Street, Suite 750, Houston, TX 77030; email: ccwmd@houstonretina.com. doi: 10.3928/23258160-20180329-08
Publisher Copyright:
© 2018 Slack Incorporated. All rights reserved.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - BACKGROUND AND OBJECTIVE: Longitudinal quantification of retinal nonperfusion (RNP) in eyes with retinal vein occlusion (RVO) undergoing anti-vascular endothelial growth factor therapy. PATIENTS AND METHODS: Thirty eyes with ischemic RVO were randomized to ranibizumab (Lucentis; Genentech, South San Francisco, CA) (monotherapy) or ranibizumab plus peripheral laser (combination therapy) in a 12-month, prospective trial. RNP on fluorescein angiography was quantified within the macula through 12 months of follow-up. RESULTS: Baseline mean macular RNP areas were 5.04 mm
2 and 8.30 mm
2 in the monotherapy (n = 5) and combination therapy (n = 15) cohorts, respectively. Through month 12, mean macular RNP area increased 0.36 mm
2 and 0.53 mm
2 in the monotherapy and combination therapy cohorts, respectively (P = .77). Marked, progressive RNP was observed in three eyes (12%). No areas of reperfusion were detected in any eye. CONCLUSION: Among ischemic RVO eyes in WAVE, macular RNP was common at baseline and remained stable over time in most eyes, though marked RNP progression occurred in a minority of eyes.
AB - BACKGROUND AND OBJECTIVE: Longitudinal quantification of retinal nonperfusion (RNP) in eyes with retinal vein occlusion (RVO) undergoing anti-vascular endothelial growth factor therapy. PATIENTS AND METHODS: Thirty eyes with ischemic RVO were randomized to ranibizumab (Lucentis; Genentech, South San Francisco, CA) (monotherapy) or ranibizumab plus peripheral laser (combination therapy) in a 12-month, prospective trial. RNP on fluorescein angiography was quantified within the macula through 12 months of follow-up. RESULTS: Baseline mean macular RNP areas were 5.04 mm
2 and 8.30 mm
2 in the monotherapy (n = 5) and combination therapy (n = 15) cohorts, respectively. Through month 12, mean macular RNP area increased 0.36 mm
2 and 0.53 mm
2 in the monotherapy and combination therapy cohorts, respectively (P = .77). Marked, progressive RNP was observed in three eyes (12%). No areas of reperfusion were detected in any eye. CONCLUSION: Among ischemic RVO eyes in WAVE, macular RNP was common at baseline and remained stable over time in most eyes, though marked RNP progression occurred in a minority of eyes.
KW - Journal Article
UR - http://www.scopus.com/inward/record.url?scp=85046149458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046149458&partnerID=8YFLogxK
U2 - 10.3928/23258160-20180329-08
DO - 10.3928/23258160-20180329-08
M3 - Article
C2 - 29664983
SN - 2325-8160
VL - 49
SP - 258
EP - 264
JO - Ophthalmic surgery, lasers & imaging retina
JF - Ophthalmic surgery, lasers & imaging retina
IS - 4
ER -